Correction to Structure-Activity Relationship Study of N(6)-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N(6)-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine Analogues: Development of Highly Selective D3 Dopamine Receptor Agonists along with a Highly Potent D2/D3 Agonist and Their Pharmacological Characterization.
作者信息
Johnson Mark, Antonio Tamara, Reith Maarten E A, Dutta Aloke K
出版信息
J Med Chem. 2013 Jan 24;56(2):589-90. doi: 10.1021/jm301634c. Epub 2013 Jan 4.
Abstract
摘要
相似文献
1
Correction to Structure-Activity Relationship Study of N(6)-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N(6)-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine Analogues: Development of Highly Selective D3 Dopamine Receptor Agonists along with a Highly Potent D2/D3 Agonist and Their Pharmacological Characterization.N(6)-(2-(4-(1H-吲哚-5-基)哌嗪-1-基)乙基)-N(6)-丙基-4,5,6,7-四氢苯并[d]噻唑-2,6-二胺类似物的构效关系研究校正：高选择性D3多巴胺受体激动剂以及高效D2/D3激动剂的开发及其药理学特性
J Med Chem. 2013 Jan 24;56(2):589-90. doi: 10.1021/jm301634c. Epub 2013 Jan 4.
2
Structure-activity relationship study of N⁶-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N⁶-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine analogues: development of highly selective D3 dopamine receptor agonists along with a highly potent D2/D3 agonist and their pharmacological characterization.N⁶-(2-(4-(1H-吲哚-5-基)哌嗪-1-基)乙基)-N⁶-丙基-4,5,6,7-四氢苯并[d]噻唑-2,6-二胺类似物的构效关系研究：高选择性 D3 多巴胺受体激动剂的开发以及一种高活性 D2/D3 激动剂及其药理学特性。
J Med Chem. 2012 Jun 28;55(12):5826-40. doi: 10.1021/jm300268s. Epub 2012 Jun 13.
3
Development of a Highly Potent D2/D3 Agonist and a Partial Agonist from Structure-Activity Relationship Study of N(6)-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N(6)-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine Analogues: Implication in the Treatment of Parkinson's Disease.基于N(6)-(2-(4-(1H-吲哚-5-基)哌嗪-1-基)乙基)-N(6)-丙基-4,5,6,7-四氢苯并[d]噻唑-2,6-二胺类似物构效关系研究开发高效D2/D3激动剂和部分激动剂：对帕金森病治疗的意义
J Med Chem. 2015 Dec 10;58(23):9179-95. doi: 10.1021/acs.jmedchem.5b01031. Epub 2015 Nov 30.
4
Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior.多巴胺激动剂诱导大鼠打哈欠：一种由多巴胺D3受体介导的行为。
J Pharmacol Exp Ther. 2005 Jul;314(1):310-9. doi: 10.1124/jpet.105.085472. Epub 2005 Apr 15.
5
Synthesis and biological characterization of novel hybrid 7-[[2-(4-phenyl-piperazin-1-yl)-ethyl]-propyl-amino]-5,6,7,8-tetrahydro-naphthalen-2-ol and their heterocyclic bioisosteric analogues for dopamine D2 and D3 receptors.新型杂化7-[[2-(4-苯基-哌嗪-1-基)-乙基]-丙基-氨基]-5,6,7,8-四氢萘-2-醇及其多巴胺D2和D3受体的杂环生物电子等排体类似物的合成与生物学特性研究
Bioorg Med Chem. 2004 Aug 15;12(16):4361-73. doi: 10.1016/j.bmc.2004.06.019.
6
Development of (S)-N6-(2-(4-(isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine and its analogue as a D3 receptor preferring agonist: potent in vivo activity in Parkinson's disease animal models.（S）-N6-（2-（4-（异喹啉-1-基）哌嗪-1-基）乙基）-N6-丙基-4,5,6,7-四氢苯并[d]噻唑-2,6-二胺及其类似物作为 D3 受体优先激动剂的开发：在帕金森病动物模型中的强效体内活性。
J Med Chem. 2010 Feb 11;53(3):1023-37. doi: 10.1021/jm901184n.
7
Interaction of D₃ preferring agonist (-)-N⁶-(2-(4-(biphenyl-4-yl)piperazin-1-yl)ethyl)-N⁶-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine (D-264) with cloned human D₂L, D₂S, and D₃ receptors: potent stimulation of mitogen-activated protein kinases and G protein-coupled inward rectifier potassium channels.D₃ 受体偏好激动剂 (-)-N⁶-(2-(4-(联苯-4-基)哌嗪-1-基)乙基)-N⁶-丙基-4,5,6,7-四氢苯并[d]噻唑-2,6-二胺 (D-264) 与克隆人 D₂L、D₂S 和 D₃ 受体的相互作用：强烈刺激丝裂原激活的蛋白激酶和 G 蛋白偶联内向整流钾通道。
Naunyn Schmiedebergs Arch Pharmacol. 2013 Feb;386(2):97-105. doi: 10.1007/s00210-012-0811-6. Epub 2012 Nov 20.
8
Structural modifications of neuroprotective anti-Parkinsonian (-)-N6-(2-(4-(biphenyl-4-yl)piperazin-1-yl)-ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine (D-264): an effort toward the improvement of in vivo efficacy of the parent molecule.神经保护抗帕金森氏症化合物 (-)-N6-(2-(4-(联苯-4-基)哌嗪-1-基)-乙基)-N6-丙基-4,5,6,7-四氢苯并[d]噻唑-2,6-二胺 (D-264) 的结构修饰：提高母体分子体内疗效的努力。
J Med Chem. 2014 Feb 27;57(4):1557-72. doi: 10.1021/jm401883v. Epub 2014 Feb 12.
9
Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)quinolin-8-ol and its analogues as highly potent dopamine D2/D3 agonists and as iron chelator: in vivo activity indicates potential application in symptomatic and neuroprotective therapy for Parkinson's disease.发现 4-(4-(2-((5-羟基-1,2,3,4-四氢萘-2-基)(丙基)氨基)乙基)哌嗪-1-基)喹啉-8-醇及其类似物作为高效多巴胺 D2/D3 激动剂和铁螯合剂：体内活性表明其在帕金森病的症状性和神经保护性治疗中有潜在应用。
J Med Chem. 2010 Mar 11;53(5):2114-25. doi: 10.1021/jm901618d.
10
Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.新型N-{4-[4-(2,3-二氯苯基)哌嗪-1-基]丁基}芳基羧酰胺的杂环反式烯烃类似物作为对多巴胺D3受体具有高亲和力的选择性探针。
J Med Chem. 2005 Feb 10;48(3):839-48. doi: 10.1021/jm049465g.
引用本文的文献
1
Development of a Highly Potent D2/D3 Agonist and a Partial Agonist from Structure-Activity Relationship Study of N(6)-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N(6)-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine Analogues: Implication in the Treatment of Parkinson's Disease.基于N(6)-(2-(4-(1H-吲哚-5-基)哌嗪-1-基)乙基)-N(6)-丙基-4,5,6,7-四氢苯并[d]噻唑-2,6-二胺类似物构效关系研究开发高效D2/D3激动剂和部分激动剂：对帕金森病治疗的意义
J Med Chem. 2015 Dec 10;58(23):9179-95. doi: 10.1021/acs.jmedchem.5b01031. Epub 2015 Nov 30.
Zotero 插件